AFRICAN AMERICAN TOBACCO CONTROL LEADERSHIP COUNCIL, ACTION ON SMOKING AND HEALTH, AMERICAN MEDICAL ASSOCIATION, and NATIONAL MEDICAL ASSOCIATION, Plaintiffs,

vs.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; ALEX M. AZAR II, in his official capacity as Secretary of the U.S. Department of Health and Human Services; U.S. FOOD AND DRUG ADMINISTRATION; STEPHEN HAHN, in his official capacity as Commissioner of the U.S. Food and Drug Administration; CENTER FOR TOBACCO PRODUCTS; MITCH ZELLER in his official capacity as the Center for Tobacco Products, Director, Defendants.

SECOND AMENDED COMPLAINT (Administrative Procedure Act Case)
1. Plaintiffs African American Tobacco Control Leadership Council ("AATCLC"), Action on Smoking on Health ("ASH"), American Medical Association ("AMA"), and National Medical Association ("NMA") allege, upon knowledge as to themselves, and upon information and belief as to all other matters, as follows:

INTRODUCTION


3. Although it did not ban menthol at that time, Congress recognized that menthol cigarettes “may pose unique health risks to those who smoke them.”1 Congress was “especially concerned about proportionately higher rates of menthol cigarette use among African American smokers”; “the historic targeting of African Americans for menthol cigarette use by tobacco companies”; “the high rates of [menthol cigarette] use among … African American youth”; as well as the “higher rates of lung cancer documented among African American smokers as compared to non-African American smokers.”2

4. Congress therefore took steps to ensure that the issue of menthol in cigarettes would be “an early focus” for FDA and that FDA would have “the authority to deal with these and other products.”3 It specifically directed FDA to (1) create a Tobacco Products Scientific

---

2 Id.
Advisory Committee ("TPSAC" or "Committee"); (2) refer "[i]mmediately" to this Committee the issue of menthol in cigarettes and its effect on public health; and (3) reevaluate periodically the flavor ban (which had omitted menthol) "to determine whether such standard[] should be changed to reflect new medical, scientific, or other technological data," including with respect to menthol. See 21 U.S.C. § 387g(a)(5).

5. Congress repeatedly highlighted the urgent nature of the menthol inquiry, “urg[ing] the Secretary [of the U.S. Department of Health and Human Services ("HHS") to address these issues as quickly as practicable.” H. Rept., Part 1 at 38 (emphasis added). Indeed, Congress believed that it would be “critical for the Secretary to move quickly to address the unique public health issues posed by menthol cigarettes.” Id. at 38–39 (emphasis added).

6. Following the Act’s passage, FDA formed the Tobacco Products Scientific Advisory Committee, which conducted an extensive survey assessing the scientific evidence concerning the public health impacts of menthol in cigarettes and concluded in a 2011 report that the “Removal of menthol cigarettes from the marketplace would benefit public health in the United States.” 2011 TPSAC Menthol Rept., at 225 (emphasis in original).

7. The Committee’s Report further concluded that if menthol cigarettes had been removed from the marketplace in 2010, then (a) by 2020, roughly 17,000 premature deaths would have been avoided, and about 2.3 million people would not have started smoking; and (b) by 2050, the cumulative gains would have resulted in over 327,000 premature deaths avoided, and over 9.1 million people that would not have started smoking.

8. For the African American community, this would have meant that (a) by 2020, roughly 4,700 premature deaths would have been avoided, and about 461,000 African Americans would not have started smoking; and (b) by 2050, over 66,000 premature deaths avoided.

4 See 21 U.S.C. § 387q(a); id. § 387g(e)(1).
would have been avoided, and over 1.6 million African Americans would not have started smoking.

9. FDA then conducted a peer-reviewed investigation in 2013, which reached a similar conclusion: menthol cigarettes (a) were associated with youth smoking initiation and greater addiction, and (b) posed “a public health risk above that seen with nonmenthol cigarettes.”

10. And yet, despite the findings of the TPSAC Report and FDA’s own investigation, reflecting new medical and scientific data, FDA did nothing until five years later in 2018, when then-FDA Commissioner Scott Gottlieb finally announced that FDA would advance a “Notice of Proposed Rulemaking that would seek to ban menthol in combustible tobacco products, including cigarettes and cigars.” FDA, Statement from FDA Commissioner Scott Gottlieb, M.D. (Nov. 15, 2018).5 “Now, armed with the additional years of data, comments from the public … and the perspective of [the FDA’s] Comprehensive Plan and its implementation,” FDA stated its intent to “accelerate the proposed rulemaking process to ensure that our policies on flavored tobacco products protect public health[.]” Id.

11. But instead—without engaging in any reasoned decision-making or providing any coherent explanation for its decision—FDA reversed course in or around June 2019 and decided to allow menthol to remain on the market:

   a. On June 24, 2019, the HHS published its Spring 2019 inventory of rulemaking actions under development. See Regulatory Agenda, Ofc. of the Secretary,

HHS, 84 Fed. Reg. 29623 (June 24, 2019). This Agenda presented “the regulatory activities that the Department [i.e., HHS, FDA, and the defendant Center for Tobacco Products] expect[ed] to undertake in the foreseeable future,” id. at 29624 (citing various proposed rules, final rules, and long-term actions). Absent from HHS’s Spring inventory, however, was any plan by defendants to address menthol in cigarettes, much less any explanation as to why defendants’ about-face reflected new medical, scientific, or other technological data. See HHS Regulatory Agenda, generally.

b. HHS’s Fall 2019 inventory of rulemaking actions also failed to include any reference or plan to address menthol in cigarettes, or else any explanation of defendants’ decision-making process on this important public health issue. See HHS, Agency Rule List – Fall 2019 (Dec. 26, 2019).

12. Defendants’ arbitrary and capricious actions are contrary to what the law requires, and harm the public health. And, defendants’ years of inaction and unreasonable refusal to act on this issue have almost certainly contributed to the increasing harms associated with menthol in cigarettes:

b. In 2009, more than 12 million individual smokers used menthol cigarettes. See H. Rept., Part 1 at 39. Today, the data shows that over 19 million smokers use menthol cigarettes—i.e., a majority of the estimated 34 million smokers in the United States.\(^9\)

c. In 2009, nearly 70% of African Americans who smoked, used menthol cigarettes. See H. Rept., Part 1 at 39. Today, that figure has risen to over 85%.\(^10\)

13. The COVID-19 pandemic has further showcased the myriad ways in which menthol cigarettes negatively impact the public health, and the African American community in particular. A study in the New England Journal of Medicine found that coronavirus patients in China who smoked were more than twice as likely as those who didn’t to have severe infections from COVID-19.\(^11\) An April 8, 2020 advisory from the Massachusetts Attorney General Maura Healey warned that “it is vital that people are aware of the serious potential risks associated with smoking or vaping and COVID-19,” noting that “flavored tobacco products could make lung infections like COVID-19 worse.”\(^12\) And early news reports concluded that the coronavirus was infecting and killing Black Americans at an alarmingly high rate, in part because African Americans’ higher rates of diabetes, heart disease and lung

---


\(^10\) See FDA, Menthol and Other Flavors in Tobacco Products, *id.* (noting that 85.8 percent of African American smokers use menthol cigarettes).


\(^12\) Available at [https://www.mass.gov/doc/covid-vaping-advisory/download](https://www.mass.gov/doc/covid-vaping-advisory/download).
disease—all conditions that are highly correlated with tobacco use—make people more vulnerable to the new respiratory disease.\(^\text{13}\)

14. In sum, FDA’s delay, inaction, and failure “to move quickly” has been devastating, leading to millions of people initiating smoking cigarettes, and thousands of premature deaths.

15. Plaintiff AATCLC and many others have repeatedly called for FDA to fulfill its statutory duty to re-evaluate tobacco product standards and take up a rule to ban menthol cigarettes. FDA has failed to do so, refusing even to resolve a Citizen’s Petition that AATCLC filed more than seven years ago. After these years of inaction and the untold suffering defendants have caused, plaintiffs bring this lawsuit to compel appropriate action by defendants on this critical and urgent public health issue.

**JURISDICTION & VENUE**

16. **Jurisdiction:** This Court has jurisdiction over this action, pursuant to 28 U.S.C. §§ 1331 and 1346. Plaintiffs allege violations of the Administrative Procedure Act, Pub. L. No. 404, 60 Stat. 237, ch. 324, §§ 1–12 (1946), and Section 907 of the Tobacco Control Act, 21 U.S.C. § 387g. Their requested relief is authorized by 5 U.S.C. § 706(1) and 28 U.S.C. § 1651. The United States is also a defendant.

17. **Venue:** Venue in this judicial district is appropriate, pursuant to 28 U.S.C. § 1391(c)(1). Plaintiff African American Tobacco Control Leadership Council resides in this judicial district.

18. **Intradistrict Assignment:** Pursuant to Civil L.R. 3-2(c), intradistrict assignment is proper in the San Francisco or Oakland Division, as this action arises in the County of San Francisco, where Plaintiff African American Tobacco Control Leadership Council maintains its principal place of business.

PARTIES

19. Plaintiff African American Tobacco Control Leadership Council ("AATCLC") brings this action on behalf of itself and its members. The AATCLC, which is based in San Francisco, California, was formed in 2008 to educate the African American community and public about tobacco use and cessation, and has led the fight to expose the predatory marketing of menthol cigarettes and flavored little cigars in the Black Community. The organization’s members include a cadre of dedicated community activists, academics, public health advocates, and researchers from across the country. FDA’s failure to address the harms caused by menthol in combustible cigarettes has adversely affected AATCLC, its members, and its work.

20. The AATCLC’s mission is to save lives by partnering with community stakeholders and public health agencies to inform and affect the direction of tobacco policy, practices, and priorities, particularly as it affects the lives of Black Americans and African Immigrant populations. Its work includes educating the public about the effects of tobacco on these populations, and the need to regulate flavored tobacco products, including menthol cigarettes.

21. One of the AATCLC’s key initiatives is the creation of Buffer Zones—local legislation that prohibits the sale of all flavored tobacco products, including menthol, within a 500 to 1000-foot perimeter around schools. Establishing Buffer Zones to protect inner city children reduces their access to tobacco products, de-normalizes tobacco consumption, and pushes back against predatory targeting of these communities. The AATCLC has assisted Chicago, Minneapolis-St. Paul, Baltimore, and numerous California cities in adopting and implementing Buffer Zones.

22. The AATCLC has expended and continues to expend significant resources to help create Buffer Zones and to perform other outreach, engagement and education of elected officials, clergy, community-based organizations, youth groups and the media concerning the
dangers of menthol cigarettes and their harmful effect on the lives of Black American and African Immigrant populations.

23. The defendants’ unlawful refusal to ban menthol in tobacco products, and failure to periodically reevaluate and determine (much less explain) whether the Act’s existing flavor standard should be changed to reflect new data and protect the public health, makes the AATCLC’s work more difficult and impedes its efforts to educate the public about the dangers of menthol cigarettes. It also requires the AATCLC to divert resources that could otherwise be used to advance other organizational goals to focus on menthol-related concerns.

24. In addition, as detailed below, on or about April 12, 2013, plaintiff AATCLC (together with others) submitted a Citizen Petition with the FDA. The Petition requested that the FDA take certain actions to decrease the harms caused by menthol cigarettes and provide cessation support to smokers of menthol cigarettes who wish to quit. Over seven years have passed since the AATCLC submitted this Petition, and the defendants still have not provided any substantive response.

25. Plaintiff Action on Smoking and Health (“ASH”) is a non-profit organization headquartered in Washington, D.C. ASH was founded in 1967 and has spent the last fifty years battling against the tobacco industry. Its mission is to advocate for innovative legal and policy measures to end the global tobacco epidemic. ASH’s past accomplishments include helping to achieve restrictions on tobacco advertising and smoking bans in workplaces and various forms of public transit.

26. ASH believes that the production, marketing and sale of cigarettes is a human rights violation. This is in part because the tobacco industry often targets their marketing to specific populations based on gender, race, sexual identity and age. Some of these groups smoke at much higher rates than the general population, and they are all protected by various international and regional human rights treaties and instruments. ASH is currently working to elevate tobacco as a human rights issue through (a) work with the Human Rights Council, the Framework Convention on Tobacco Control Conference of the Parties, and other
international bodies; (b) using human rights reporting mechanisms to encourage governments to advance tobacco control within their own countries; (c) providing legal resources, training, and support to advocates on how to use human rights norms to advance local tobacco control measures; and (d) maintaining a repository of human rights resources to assist allies in taking a human rights approach.

27. ASH’s efforts include menthol-related initiatives. For example, on January 2, 2020, ASH staff attended a public hearing of the D.C. City Council Judiciary and Public Safety Committee, which is considering a ban on the sale of flavored tobacco products. Both gave formal testimony in favor of the measure, and urged the Council to include menthol in the final law. ASH also provided information to the Committee concerning the Council’s authority to phase out the sale of tobacco products in the city. The defendants’ unlawful refusal to ban menthol in tobacco products, and failure to periodically reevaluate and determine whether the Act’s existing flavor standard should be changed to reflect new data and protect the public health, makes ASH’s work more difficult and impedes its efforts to educate the public about the dangers of menthol cigarettes. It also requires ASH to divert resources that could be used to advance other organizational goals to focus on menthol-related concerns.

28. Plaintiff American Medical Association (“AMA”) is an Illinois not-for-profit corporation headquartered in Chicago, Illinois. The AMA is the largest professional association of physicians, residents, and medical students in the United States. All of the state medical associations and most of the major specialty medical societies are represented in the AMA House of Delegates, with the AMA serving as the overall umbrella and voice of organized medicine in the United States. The AMA represents virtually all United States physicians, residents, and medical students through its policymaking process. AMA members practice and reside in all States, including California. AMA members practice in all areas of medical specialization.

29. The AMA’s objectives are to promote the science and art of medicine and the betterment of public health. Since its founding in 1847, the AMA has played a crucial role in
the development of medicine in the United States. For the last fifty years, it has also devoted substantial resources to anti-tobacco efforts aimed at improving public health. In keeping with this objective, the AMA and its members work tirelessly to educate the public about and protect the public from the devastating health consequences of tobacco use, the leading cause of preventable death in the United States. This work includes reviewing and synthesizing the latest scientific knowledge, preparing and distributing resources concerning tobacco use and cessation, and advocating for regulation and taxation of tobacco products at the federal, state, and local levels.

30. More recently, AMA has also increased its focus on health equity. The AMA recognizes that systemwide bias and institutionalized racism contribute to inequities across the U.S. health care system. The AMA is committed to fighting for greater health equity by identifying and eliminating inequities through advocacy, community leadership and education. This includes working to eliminate the use of menthol-flavored tobacco products, which represent a disproportionate and growing share of tobacco use by African Americans, and the direct cause of thousands of preventable deaths in the African American community. For example, the AMA has sent numerous letters to and attended meetings with government officials to encourage the elimination of menthol-flavored cigarettes.

31. The defendants’ unlawful failure to evaluate and determine whether the Act’s existing flavor standard should be changed to reflect new data and protect the public health, and to ban menthol flavoring in cigarettes, interferes with the work of the AMA and its members. Among other things, the defendants’ unlawful conduct undermines the efforts of AMA and its members to educate patients about the dangers of menthol cigarettes and achieve health equity for all patients. It also forces AMA to divert resources that could be used to advance other public health initiatives.

32. Plaintiff National Medical Association (“NMA”) is a Maryland corporation headquartered in Silver Spring, Maryland. It is a 501(c)(3) national professional and scientific organization representing the interests of more than 50,000 African American physicians and
the patients they serve—the largest and oldest such organization in the United States. The NMA is committed to improving the quality of health in communities of color and among disadvantaged people through its membership, professional development, community health education, advocacy, research and partnerships with federal and private agencies.

33. The NMA is particularly steadfast in its commitment to the elimination of health disparities and the promotion of healthy lifestyles among African Americans and other underserved populations. In furtherance of these goals, the NMA conducts national consumer education programs on cancer, cardiovascular disease and stroke, HIV/AIDS, women’s health, asthma, smoking cessation, immunization, traffic safety, breastfeeding, clinical trials, as well as other issues that impact the lives of African Americans. Throughout its history the National Medical Association has focused primarily on health issues related to African Americans and medically underserved populations; however, its principles, goals, initiatives and philosophy encompass all racial and ethnic groups.

34. As the nation’s only organization devoted to the needs of African American physicians, health professionals and their patients, the NMA serves as the conscience of the medical profession in the ongoing fight to eliminate health disparities in the nation’s health care delivery system. The NMA has been an unwavering advocate for health policies that improve the quality and availability of health care of African Americans and other underserved populations. For instance, the National Medical Association was the force behind such landmark reforms as Medicare and Medicaid. Today, the NMA continues to provide leadership in shaping the national health policy agenda through continued involvement in a variety of critical policy matters, including with respect to smoking. For example, the NMA passed an August 3, 2017 resolution during their Annual Meeting of the House of Delegates, supporting a prohibition on the sale of flavored tobacco products, including mentholated cigarettes. As noted on the NMA’s website, African Americans have the highest surveyed rate of desire to quit smoking but are less successful in quit attempts than white and Hispanic smokers. This is due in part to the anesthetic effects of menthol in mentholated cigarettes and
the high rate of mentholated cigarette use among African Americans. This is precisely the type of health disparity the NMA seeks to eliminate.

35. The defendants’ unlawful refusal to comply with their Tobacco Act obligations and address mentholated cigarettes undermines the NMA’s efforts to eliminate health disparities and promote healthy lifestyles among African Americans and other underserved populations, and impedes its mission to achieve parity and justice in medicine. Among other things, the defendants’ unlawful conduct hinders the efforts of the NMA and its members to promote smoking cessation, and forces them to divert resources that could be used for other health policies.


37. Defendant Alex M. Azar II is sued in his official capacity as the Secretary of the U.S. Department of Health and Human Services. As Secretary, Mr. Azar is ultimately responsible for HHS’s activities and policies and for implementing the Tobacco Control Act. Although the Secretary has delegated many responsibilities under the Act to the Commissioner of the Food and Drug Administration14, the Secretary has nonetheless reserved the authority to (a) establish procedural rules applicable to tobacco products, such as menthol cigarettes; and (b) present highly significant public issues involving the availability and marketability of tobacco products, including menthol cigarettes.

38. Defendant U.S. Food and Drug Administration (“FDA”) is the federal agency charged with regulating the marketing of tobacco products in the United States, including menthol in combustible cigarettes. By statute, FDA “shall (1) promote the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the

marketing of regulated products in a timely manner[.]” 21 U.S.C. § 393(b); see also Tobacco Control Act findings, P.L. 111–31, Div A, § 2, 123 Stat. 1776, 1780 (June 22, 2009) (noting further that FDA possesses a “mandate to promote health and reduce the risk of harm”). FDA is headquartered in Silver Spring, Maryland.

39. Defendant Stephen Hahn is sued in his official capacity as Commissioner of the FDA. FDA administers programs at HHS related to tobacco products. As Commissioner, Mr. Hahn is responsible for FDA’s activities and policies, including the agency’s implementation of the Tobacco Control Act.

40. Defendant Center for Tobacco Products is the federal agency responsible for implementing the Tobacco Control Act and related matters assigned by the FDA Commissioner. See 21 U.S.C. § 387a(e). This Center is established within FDA and reports to the FDA Commissioner. See id. The Center is headquartered in Silver Spring, Maryland.

41. Defendant Mitch Zeller is sued in his official capacity as the Center for Tobacco Products, Director. The Center implements the Secretary and FDA’s responsibilities under the Tobacco Control Act.

FACTUAL & LEGAL BACKGROUND

42. This section sets forth defendants’ obligations and their failure to “quickly” address the public health issue of menthol in cigarettes, to undertake a “periodic evaluation of tobacco product standards,” and to make a determination based on “new medical, scientific, or other technological data.”

I. FDA and The Tobacco Control Act

43. As shown below, FDA is well-aware of the critical public health issues and harms surrounding menthol in cigarettes. Nonetheless, FDA has unreasonably delayed and

15 This complaint accordingly refers defendants’ obligations globally where applicable, and specifies the relevant defendant when a particular defendant has a unique role.
unlawfully withheld its duty to evaluate and determine whether to issue a tobacco product
standard aimed at removing menthol from cigarettes for the protection of public health.

44. The FDA’s knowing inaction on this issue is contrary to FDA’s mission
statement and statutory obligations, as well as Congress’s expressed intent and direction to
defendants when enacting the Tobacco Control Act.

A. FDA’s mission is to protect the public health.

45. By statute, FDA’s mission is to “promote the public health by promptly and
efficiently reviewing clinical research and taking appropriate action on the marketing of regulated

46. This mission includes “regulating the manufacturing, marketing, and
distribution of tobacco products to protect the public health and reduce tobacco use by
minors,” FDA.gov, What We Do,16 as well as “[p]rotecting consumers and enhancing public
health by maximizing compliance of FDA regulated products and minimizing risk associated

47. HHS and FDA are also responsible for “identifying and addressing …
disproportionately high and adverse human health … effects of its programs, policies, and
activities on minority populations and low-income populations[.]” Executive Order 12898,
§ 1-101 (Feb. 11, 1994).18

16 Available at https://www.fda.gov/about-fda/what-we-do.
17 Available at https://www.fda.gov/media/71923/download. The Regulatory Procedures
Manual “is a reference manual that provides internal procedures and related information to be
used by FDA employees who process certain regulatory and enforcement matters in support of
the agency’s public health mission.” FDA Reg. Procedures Manual at 1. This Manual further
identifies some of FDA’s values, including the following: “We demonstrate our commitment to
safeguarding the public health in our actions.” Id. at 3.
B. Congress directed FDA to move quickly to address menthol.

48. Section 907 of the Tobacco Control Act sets forth FDA’s obligation to address the public health problems caused by menthol cigarettes. See 21 U.S.C. § 387g.

1. The Act mandates action by the Secretary on menthol.

49. As noted above, when Congress enacted the Tobacco Control Act in 2009, Congress created a “tobacco product standard” that effectively banned all flavors in cigarettes, save for tobacco and menthol flavors. See 21 U.S.C. § 387g(a)(1)(A).19

50. Significantly, however, this standard did not “limit the Secretary’s [i.e., FDA’s] authority to take action under this section or other sections of this Act applicable to menthol,” 21 U.S.C. § 387g(a)(1)(A); see also H. Rept., Part 1 at 4 (granting FDA “the authority to require product changes in current and future tobacco products, such as the reduction or elimination of ingredients, additives, and constituents”).

51. On the contrary, Congress expressly directed defendants to move quickly to gather evidence concerning “the impact of the use of menthol in cigarettes on the public health, including such use among children, African-Americans, Hispanics, and other racial and ethnic minorities,” 21 U.S.C. § 387g(c)(1), and then determine whether the tobacco product standard should be changed to ban it. 21 U.S.C. § 387g(a)(5).

52. In particular, the Act mandates further investigation concerning the use of menthol in cigarettes and requires that FDA “shall periodically evaluat[e]” the “tobacco product standards established under this section[, including the previously identified flavor ban, 21 U.S.C. § 387g(a)(1)(A)], to determine whether such standards should be changed to reflect new medical, scientific, or other technological data.” 21 U.S.C. § 387g(a)(5) (“Periodic Reevaluation of Tobacco Product Standards”).

53. Taken together then, these above-identified subsections require FDA to (a) periodically re-evaluate the existing tobacco product standard, which does not currently ban menthol in cigarettes; and (b) “determine” whether such standard “should be changed” to (i) reflect new data, and (ii) to protect the public health.

Page 16 of 47
2. The Act creates an advisory committee to assist FDA.

54. To assist FDA in making that determination, Congress directed FDA to create a Tobacco Products Scientific Advisory Committee. See 21 U.S.C. § 387g(c)(1).

55. Per the Act, FDA “shall refer to the Committee for report and recommendation … the issue of the impact of the use of menthol in cigarettes on the public health, including such use among children, African-Americans, Hispanics, and other racial and ethnic minorities.” 21 U.S.C. § 387g(c)(1).

56. The Committee’s review was also directed to address the considerations identified by subsections (a)(3)(B)(i) and (b)—i.e., considerations that FDA would have otherwise addressed in adopting an additional tobacco product standard or in considering any proposed standard. See 21 U.S.C. § 387g(c)(1).

57. Such considerations would include “scientific evidence” concerning the risks and benefits of a “proposed standard,” 21 U.S.C. § 387g(a)(3)(B)(i); “the technical

---

19 Per the Act, “a cigarette or any of its component parts” is prohibited from containing “as a constituent … or additive, an artificial or natural flavor (other than tobacco or menthol) or an herb or spice, including strawberry, grape, orange, clove, cinnamon, pineapple, vanilla, coconut, licorice, cocoa, chocolate, cherry, or coffee, that is a characterizing flavor of the tobacco product or tobacco smoke.” 21 U.S.C. § 387g(a)(1)(A). This standard became effective on September 22, 2009. See FDA, Enforcement of General Tobacco Standard Special Rule for Cigarettes, 74 Fed. Reg. 48974, Docket No. FDA-2009-N-0449 (Sept. 22, 2009).

20 “In making a finding described in subparagraph (A), [FDA] shall consider scientific evidence concerning (I) the risks and benefits the risks and benefits to the population as a whole, including users and nonusers of tobacco products, of the proposed standard; (II) the increased or decreased likelihood that existing users of tobacco products will stop using such products; and (III) the increased or decreased likelihood that those who do not use tobacco products will start using such products.” 21 U.S.C. § 387g(a)(3)(B)(i).

21 “[FDA] shall consider information submitted in connection with a proposed standard regarding the technical achievability of compliance with such standard.” 21 U.S.C. § 387g(b)(1). “[FDA] shall consider all other information submitted in connection with a proposed standard, including information concerning the countervailing effects of the tobacco product standard on the health of adolescent tobacco users, adult tobacco users, or nontobacco users, such as the creation of a significant demand for contraband or other tobacco products that do not meet the requirements of this chapter and the significance of such demand.” Id. § 387g(b)(2).
achievability of compliance with such standard,” *id.* § 387g(b)(1); and “other information
submitted in connection with a proposed standard,” *id.* § 387g(b)(2).

58. Congress further mandated that “not later than 1 year after its establishment,”
the Scientific Advisory Committee “shall submit to the Secretary a report and
recommendation,” 21 U.S.C. § 387g(e)(2), and reiterated that nothing in subsection (e) was to
be construed as limiting FDA’s “authority to take action under this section or other sections of
this Act applicable to menthol,” *id.* § 387g(e)(2), (3).

3. Congress intended FDA to address menthol “quickly.”

cosponsors introduced H.R. 1256—the “Family Smoking Prevention and Tobacco Control
Act.” The Committee Report and floor statements of the sponsor and committee member in
charge (Rep. Waxman) make clear that Congress considered menthol to be an urgent public
health concern and intended the FDA to move quickly to address it.

60. Both the accompanying Committee Report and following floor statements by
Rep. Waxman confirm Congress’ intention that FDA act “quickly” to address the special
problem of menthol cigarettes. As explained by the Committee Report:

`Section 907. Tobacco product standards` Consistent with the overall
intent of the bill to protect the public health, including by reducing
the number of children and adolescents who smoke cigarettes,
section 907(a)(1) is intended to prohibit the manufacture and sale
of cigarettes with certain “characterizing flavors” that appeal to
youth. …

*The Committee recognizes the unique issues surrounding menthol cigarettes and urges the Secretary
to address these issues as quickly as practicable.* The
Committee is especially concerned about proportionately higher
rates of menthol cigarette use among African American smokers,
as well as the historic targeting of African Americans for menthol cigarette use by tobacco companies. While it is unclear what effect the presence of menthol in cigarettes may have on addictiveness, toxicity, or other qualities of cigarettes, the Committee recognizes that menthol cigarettes may pose unique health risks to those who smoke them. Given the high rates of use among African American smokers, including African American youth, as well as higher rates of lung cancer documented among African American smokers as compared to non-African American smokers, the Committee believes that it is critical for the Secretary to move quickly to address the unique public health issues posed by menthol cigarettes.


61. This emphasis on FDA’s ability to move “quickly” in addressing “the unique public health issues posed by menthol cigarettes” was further emphasized by Rep. Henry A.

---

22 The House Committee Report went on to note the following:

Menthol cigarettes currently represent over one quarter of all cigarettes smoked in the United States, representing more than 12 million individual smokers. Additionally, nearly 7 in 10 African Americans who smoke choose to smoke menthol cigarettes. Given the number of open questions related to menthol cigarettes, the legislation authorizes the Secretary to ban or modify the use of menthol in cigarettes based on scientific evidence. Given the large number of Americans who smoke menthol, the disproportionate prevalence of menthol cigarettes among African Americans, the racial and ethnic differences in lung cancer incidence, and the uncertainty about the potentially negative consequences of an immediate menthol ban, the Committee believes that this approach ensures that FDA has the scientific evidence necessary to make the best decisions to protect the public health.

Waxman, the committee member in charge of H.R. 1256. On two separate occasions, Rep. Waxman noted that menthol cigarettes would be “an early focus” of FDA’s attention.

62. First, on April 1, 2009, Rep. Waxman noted that he and his colleagues had “worked with members of the Congressional Black Caucus to ensure that menthol cigarettes will be an early focus of the agency’s attention.” Cong. Rec.—House, H4318, H4339 (Vol. 155, No. 55).23

63. Then, on June 12, 2009, Rep. Waxman reiterated that same understanding, using similarly strong language: “We worked with members of the Congressional Black Caucus to ensure that menthol cigarettes will be an early focus of attention by the agency, and that the agency has the authority to deal with these and other products.” Cong. Rec.—House, H6630, H6652 (Vol. 155, No. 88).24

C. FDA confirmed its intention to address menthol in cigarettes.


66. FDA’s own statements following the Act’s passage reflect that FDA intended to address menthol in cigarettes, following the issuance of the Tobacco Products Scientific Advisory Committee’s report and recommendation.

67. On September 22, 2009, FDA announced that it would be “examining options” for regulating menthol cigarettes:


The FDA’s ban on candy and fruit-flavored cigarettes, effective
today, highlights the importance of reducing the number of
children who start to smoke, and who become addicted to
dangerous tobacco products. The FDA is also examining options
for regulating both menthol cigarettes and flavored tobacco
products other than cigarettes.\footnote{FDA, News & Events, Candy and Fruit Flavored Cigarettes Now Illegal in United States; Step is First Under New Tobacco Law (Sept. 22, 2009) [noting that “[a]lmost 90 percent of adult smokers start smoking as teenagers. These flavored cigarettes are a gateway for many children and young adults to become regular smokers,” said FDA Commissioner Margaret A. Hamburg, M.D. … Flavors make cigarettes and other tobacco products more appealing to youth. Studies have shown that 17 year old smokers are three times as likely to use flavored cigarettes as smokers over the age of 25. … “FDA’s ban on these cigarettes will break that cycle for the more than 3,600 young people who start smoking daily.”] (footnote omitted). Available at https://web.archive.org/web/20090924140101/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm183211.htm.}

68. In response to questions from journalists, Dr. Lawrence Deyton—the Center for Tobacco Products, Director at such time—noted that the Center would be “studying” and “discussing” the issue of menthol cigarettes with the agency’s Scientific Advisory Committee:

Jennifer Corbett: The question I have is—and you mentioned in your press release—that you’re looking at menthol cigarettes, because my understanding (about) is the—that’s the biggest flavor out there that …

Lawrence Deyton: Yes, the menthol issue is also specifically addressed in the Family Smoking Prevention and Tobacco Control Act, and that is an issue again which we will be discussing with our Scientific Advisory Committee and studying. \textit{We’ve been}
asked specifically by the [A]ct to study that.

Sept. 22, 2009 Tr. For FDA’s Media Briefing, at 8–9 (emphasis added).26

69. In similar statements, Dr. Deyton reiterated that the Center would be addressing the issue of menthol cigarettes “separately”:

Miriam Falco: … I got to say I’m a little confused. Your answers are all very government-speak, if I may say so. If you know that young people prefer menthol cigarettes, then why aren’t they included in this? …

Lawrence Deyton: In terms of the question of menthol, the law specifically asks us to look at menthol separately. And we will be doing that.

Id. at 15 (emphasis added).

II. FDA concludes that banning menthol would improve the public health.

70. Following the Tobacco Control Act’s enactment, FDA collected extensive evidence concerning these critical public health issues.

A. The 2011 Tobacco Products Scientific Advisory Committee Report

71. In 2010, FDA organized a Tobacco Product Scientific Advisory Committee (“TPSAC”) in accordance with the Act’s directive. That Committee was comprised of “a panel of leading public health, scientific experts and representatives of various parts of the tobacco industry.” See FDA, Dr. Lawrence R. Deyton, Dir. Center for Tobacco Products, FDA Remarks on the Report and Recommendation on the Public Health Impact of Menthol Cigarettes (Mar.

18, 2011) (“2011 FDA Remarks on Menthol Cigarettes Rept.”). 27 This Committee was charged with “providing advice, information, and recommendations to FDA on health issues related to tobacco products and other issues relating to the regulation of tobacco products.” Id.

72. As part of the Committee’s charter, FDA designated a government representative to attend each meeting of the full committee and subcommittees; ensure the Committee’s compliance with statutory, regulatory, and administrative directives; and approve and prepare all meeting agendas. See FDA, Charter of the Tobacco Products Scientific Advisory Comm. (Aug. 7, 2009). 28

73. The full Scientific Advisory Committee first met in March 2010, and 11 more times thereafter. See FDA Rept. to Congress, Progress and Effectiveness of the Implementation of the Family Smoking Prevention and Tobacco Control Act, at 15 (2013). There were also two meetings of the Tobacco Products Constituents Subcommittee of the TPSAC and two meetings of the Menthol Report Subcommittee. See id. Each of these Committee and Subcommittee meetings covered a broad range of materials, presentations, and public submissions. See FDA 2010 TPSAC Mtg. Materials and Info.; 29 see also FDA 2011 TPSAC Mtg. Materials and Info. 30


75. This Report—also known as the TPSAC Report—contained a number of findings and conclusions, based on the best available scientific evidence.

1. **Menthol masks the irritating effects of nicotine.**

76. Among other things, the Report found that menthol is a flavor additive that possesses a minty taste and aroma. *See* 2011 TPSAC Menthol Rept. at 16. In certain medicinal products such as cough drops, menthol is regulated as a drug. *See* id. The use of menthol in tobacco products, however, was not. *See* id. Menthol is present in 90% of tobacco products, including cigarettes that are not marketed as menthol cigarettes. *See* id.

77. The Report also found that menthol produces a variety of sensory effects, including cooling and soothing effects, as well as anesthetic effects. *See* id. at 23. For example, “[i]n cigarettes with low levels of tar and nicotine, the addition of menthol can enhance the ‘bite’ or ‘throat grab’ of the smoke, making such cigarettes more acceptable to consumers. Conversely, the addition of menthol to cigarettes high in tar and nicotine can reduce the irritating effect of nicotine … making these cigarettes more palatable.” *Id.* at 24.

78. Significantly, the Report found that the tobacco companies “manipulated the concentration of menthol to achieve a desired taste, aroma, and cooling sensation based on anticipated consumer preference and demand.” *See* id. at 55.

2. **The marketing of menthol cigarettes to youth and minorities.**

79. The Report also found that the tobacco industry spent “as much or more on magazine advertising for menthol [cigarette brands] as for non-menthol brands, even though

---

menthol brands represent a much smaller share of the market.” 2011 TPSAC Menthol Rept. at 61. In particular, the Committee found that—

a. menthol cigarettes “are marketed disproportionately to younger people,” id. at 92;

b. menthol use is higher among youth and young adult smokers, see id.;

c. women “have been targets of tailored menthol marketing efforts,” id.; and

d. menthol cigarettes are “disproportionately marketed per capita to African Americans. African Americans have been the subjects of specifically tailored menthol marketing strategies and messages. … [And,] [c]onsistent with these targeted marketing efforts, menthol cigarettes are disproportionately smoked by African American smokers,” id.

80. The Report further found that “although cigarette smoking is becoming less prevalent, menthol cigarette smoking is declining at [a] slower rate than is non-menthol cigarette smoking.” Id. at 148.

81. In addition, menthol cigarettes were associated with “increased transition to greater or established smoking and dependence.” Id. at 149.

82. In sum, the Report noted that sufficient evidence existed to conclude that the availability of menthol cigarettes—

a. increases experimentation and regular smoking, id. at 216;

b. increases the likelihood of addiction and the degree of addiction in youth smokers, id. at 216; and

c. results in lower likelihood of smoking cessation success in African Americans, compared to smoking non-menthol cigarettes, id. at 217.

83. The availability of menthol cigarettes was also found to “increase the likelihood of experimentation and regular smoking beyond the anticipated prevalence if such cigarettes were not available, in the general population and particularly in African Americans.” id. at 219. In addition, the Committee found a “causal relationship between the availability of
menthol cigarettes and regular smoking among youth.” *Id.* And, it found that menthol cigarette marketing increased the prevalence of smoking “beyond anticipated prevalence if such cigarettes were not available for the whole population, and for youth and African Americans.” *Id.* at 220.

### 3. Conclusion: Menthol cigarettes harm the public health.

84. Based on the Committee’s findings, the Report made two overall conclusions: (1) “Menthol cigarettes have an adverse impact on public health in the United States”; and (2) “There are no public health benefits of menthol compared to non-menthol cigarettes.” 2011 TPSAC Menthol Rept. at 220.

85. As explained by the Committee, “the availability of menthol cigarettes has led to an increase in the number of smokers and [] this increase does have adverse public health impact in the United States.” *Id.* at 220.

86. “[O]f particular concern was the high rate of menthol cigarette smoking among youth and the trend over the last decade of increasing menthol cigarette smoking among 12–17 year olds, even as smoking of non-menthol cigarettes declines. …. Thus, the availability of menthol cigarettes increases initiation and reduces cessation, thereby increasing the number of people who are smoking. This increase in the number of smokers represents an adverse impact of the availability of menthol cigarettes on public health.” *Id.* at 220–21.

87. Notably, the Committee found that if menthol cigarettes had been removed from the market in 2010, then by 2020, roughly 17,000 premature deaths would have been avoided, and about 2.3 million people would not have started smoking. By 2050, the cumulative gains would have resulted in over 327,000 premature deaths avoided, and over 9.1 million people that would not have started smoking. *See id.* at 221.

88. For African Americans, this would have meant that by 2020, roughly 4,700 premature deaths would have been avoided, and about 461,000 African Americans would not have started smoking. By 2050, over 66,000 premature deaths would have been avoided, and over 1.6 million African Americans would not have started smoking. *See id.* at 223.
4. **Recommendation: Remove menthol cigarettes from the market.**

89. As a result of the Committee’s findings and conclusions, the Committee then made the following overall recommendation to FDA: “*Removal of menthol cigarettes from the marketplace would benefit public health in the United States.*” [2011 TPSAC Menthol Rept. at 225 (emphasis in original)].

90. Per the Committee, the tobacco companies’ marketing of menthol cigarettes “has been successful”:

- Menthol cigarettes are now smoked by most African American smokers and there is a concerning rise of menthol cigarette smoking among youth. Menthol cannot be considered merely a flavoring additive to tobacco. Its pharmacological actions reduce the harshness of smoke and the irritation from nicotine, and may increase the likelihood of nicotine addiction in adolescents and young adults who experiment with smoking. Furthermore, the distinct sensory characteristics of menthol may enhance the addictiveness of menthol cigarettes, which appears to be the case among youth. [The Committee] has found that the availability of menthol cigarettes has an adverse impact on public health by increasing the numbers of smokers with resulting premature death and avoidable morbidity. *Id.* at 225.

91. Removing menthol from cigarettes could furthermore result in a substantial reduction in cigarette smoking by encouraging smokers to quit smoking. *See id.* at 227.

5. **FDA’s re-commitment to addressing menthol in cigarettes.**

92. Following the Committee’s release of this report, FDA announced that it would conduct a “thorough review” of the report, with its own experts within the FDA Center for Tobacco Products. *2011 FDA Remarks on Menthol Cigarettes Rept.* FDA further
acknowledged “the strong interest in this issue among all stakeholders” and committed itself to
“continu[ing] to communicate the steps FDA is taking as it determines what future regulatory
actions, if any, are warranted.”  *Id.*

93.  FDA then reiterated that “a top priority for FDA is to protect the public health
from the harmful effects of tobacco use[.]”  *Id.*

94.  Per FDA’s Center for Tobacco Products Director, “Tobacco is the leading
cause of preventable disease, disability, and death in the United States. Tobacco products are
responsible for approximately 443,000 deaths and $193 billion on medical expenditures and
lost productivity each year in the United States.”  *Id.*

**B. FDA’s 2013 scientific evaluation of menthol cigarettes.**

95.  On July 24, 2013, FDA then issued an advance notice of proposed rulemaking
to solicit information and public comment on the “potential regulation of menthol in

96.  As part of this advance notice, FDA made available its preliminary scientific
evaluation of public health issues relating to the use of menthol in cigarettes.  See FDA, Prelim.
Scientific Eval. of the Possible Public Health Effects of Menthol Versus Non[-]Menthol
Cigarettes (‘‘2013 FDA Findings’’). This undertaking was a “thorough review of the available
science concerning menthol cigarettes.”  *Id.*  at 3.  To accomplish this task, FDA—

---

32 At around this same time, the tobacco industry submitted to FDA a competing Industry


34 See FDA, Advance Notice of Proposed Rulemaking, *Menthol in Cigarettes, Tobacco Products*, 78
Fed. Reg. 44484, at Reference 1, Preliminary Scientific Evaluation of the Possible Public Health Effects of
Menthol Versus non[-]Menthol Cigarettes, ID No. FDA-2013-N-0521-0001 (July 24, 2013).  Available at
a. “weighed the collective body of evidence for the impact of the use of menthol in cigarettes on public health”;

b. “considered the source of information, the type of study, and the quality of study methods and data”;

c. “evaluated the peer-reviewed literature, industry submissions and other materials provided to TPSAC,” and
d. “performed or commissioned additional analyses in an attempt to fill in and inform some of the gaps in the literature.”

Id. at 3.

97. FDA then submitted its findings to a peer review panel, which provided comments to which FDA then responded to. See FDA Rept. to Congress, Progress and Effectiveness of the Implementation of the Family Smoking Prevention and Tobacco Control Act, at 15 (2013). The agency also posted the peer reviewed comments, and its response to those comments. See id.

1. FDA’s 2013 findings affirm the Committee’s 2011 findings.

98. Based on FDA’s review, FDA found that the weight of the evidence, among other things, supported the following conclusions:

a. Menthol in cigarettes is “likely associated with altered physiological responses to tobacco smoke”;

b. A majority of African American smokers use menthol cigarettes;

c. Younger populations have the highest rate of smoking menthol cigarettes;

d. Female smokers are more likely to smoke menthol cigarettes than male smokers;

e. The marketing of menthol cigarettes is associated with menthol brand preference among adolescents and the African American community; and

35 Available at https://www.fda.gov/media/86670/download.

36 “The available data show that advertising is a strong driver of brand preference among adolescents and that it is likely that the standard marketing mix approach of price, promotion,
f. Menthol in cigarettes is likely associated with—
   i. increased initiation and progression to regular cigarette smoking;37
   ii. increased dependence;38 and
   iii. reduced success in smoking cessation, especially among African
       American menthol smokers.39

2013 FDA Findings at 4–6.

99. In summary, FDA concluded that menthol in cigarettes was associated with
greater addiction, menthol smokers were less likely to successfully quit smoking, and that
menthol cigarettes likely posed “a public health risk above that seen with nonmenthol
cigarettes”:

The impact of cigarette smoking upon public health is
indisputable. More than 400,000 deaths per year in the United
States are caused by tobacco use. Consistent patterns have
emerged as a result of FDA’s evaluation of the scientific evidence
relevant to the impact of menthol tobacco products on public
health. … [A]dequate data suggest that menthol use is likely
associated with increased smoking initiation by youth and young
adults. Further, the data indicate that menthol in cigarettes is

37 “Data show that newer smokers prefer menthol at levels substantially above that of the general
population, with an inverse correlation between age and menthol preference that reaches a
plateau in adulthood.” 2013 FDA Findings, at 5.

38 “There were consistent findings that menthol smokers more likely to smoke their first cigarette
within five minutes of waking.” 2013 FDA Findings, at 6.

39 “In the reviewed studies, menthol smokers, especially African American menthol smokers,
were less likely to successfully stop smoking than their nonmenthol smoking counterparts. This is
consistent with the observation that menthol smokers appear to be more nicotine dependent than
nonmenthol smokers which can be an important factor in smoking cessation success.” 2013 FDA
Findings, at 6.
likely associated with greater addiction. Menthol smokers show
greater signs of nicotine dependence and are less likely to
successfully quit smoking. These findings, combined with the
evidence indicating that menthol’s cooling and anesthetic
properties can reduce the harshness of cigarette smoke and the
evidence indicating that menthol cigarettes are marketed as a
smoother alternative to nonmenthol cigarettes, make it likely that
menthol cigarettes pose a public health risk above that seen with
nonmenthol cigarettes.

Id. at 6.

2. FDA commits to addressing menthol in cigarettes.

100. Notably, FDA clarified that this “scientific assessment of public health issues
related to menthol in cigarettes … [did] not constitute a decision about what regulatory action,
if any, FDA might take with respect to menthol in cigarettes.” FDA 2013 Findings, at 7.

101. Rather, FDA would first “review[] all of the available information from this
assessment and the anticipated public comments, from the [2011 Tobacco Product Scientific
Advisory Committee] report and associated public comments, and from the tobacco industry
perspective document[.]” Id.

102. Upon completing this review, FDA would then “determine[]” whether
“restrictions on the sale and/or distribution of menthol cigarettes or product standards should
be established[.]” Id.

103. By this time, the Center for Tobacco Products’ Director Mitch Zeller had
acknowledged that “Menthol cigarettes raise critical public health questions.” Michael
Felberbaum, FDA: Menthol cigarettes likely pose health risk, USA Today (July 23, 2013).\(^{40}\) Zeller

\(^{40}\)Available at https://www.usatoday.com/story/news/nation/2013/07/23/fda-menthol-
cigarettes-health-risk/2578331/.
further noted that there was “no holdup” on FDA proposing restrictions on menthol, but that there were still “some important questions” that need to be answered. See id.

104. To that end, in August 2013, FDA announced that it was funding three menthol related studies: one to look at whether genetic differences in taste perception explain why certain racial and ethnic populations are more likely to use menthol cigarettes; the second to compare exposure to smoke-related toxins and carcinogens from menthol and nonmenthol cigarettes; and a third to examine the effects of menthol and nonmenthol compounds in various tobacco products on both tobacco addiction and toxicants of tobacco smoke. See FDA Invites Public Input on Menthol in Cigarettes, The ASCO Post, Vol. 4, Issue 13, at 21 (Aug. 13, 2013).\(^{41}\)

105. On information and belief, FDA has already completed and reviewed the results of these three menthol studies initiated almost seven years ago.

III. AATCLC’s Citizen Petition urges FDA to act on menthol, but to no avail.

106. That same year in 2013, plaintiff AATCLC (together with several other leading national organizations) submitted a Citizen Petition with FDA. See Tobacco Control Legal Consortium et al. Citizen Petition, Dkt. ID FDA-2013-P-0435-0001 (“Citizen Petition”).\(^{42}\)

107. The Petition cited extensive evidence that (a) smoking remains a critical public health issue; (b) menthol cigarettes hurt kids; (c) menthol cigarettes harm minority smokers; (d) prohibiting menthol cigarettes would benefit health, and, among other things, asked FDA to do the following:

   a. Add menthol to the list of additives and constituents in the prohibition on characterizing flavors in cigarettes and cigarette smoke directed by section 907 (a)(1)(A) of the Federal Food, Drug, and Cosmetic Act, see id. at 9–10 (i.e.

\(^{41}\) Available at https://issuu.com/ascopost/docs/tap_vol_4_issue_13.


Second Amended Complaint
Case No.: 4:20-cv-4012-KAW
prohibit menthol as a characterizing flavoring in cigarettes, see Citizen Pet., at 7); and

b. Work with appropriate entities to provide support to smokers of menthol

   cigarettes who will quit as a result of the requested prohibition on menthol in

   cigarettes, see id. at 10.

108. Roughly six months later on October 7, 2013, defendant Mitchell Zeller
   (Director, Center for Tobacco Products), writing on behalf of the defendants, responded as
   follows: “FDA has been unable to reach a decision on your petition because it raises significant,
   complex issues requiring extensive review and analysis by Agency officials. As you may know,
   FDA issued an advance notice of proposed rulemaking on July 24, 2013, seeking comments,
   including comments on FDA’s preliminary scientific evaluation of public health issues related
   to the use of menthol in cigarettes, and data, research, or other information that may inform
   regulatory actions FDA might take with respect to menthol in cigarettes (78 FR 44484). …
   We will respond to your petition as soon as we have reached a decision on your request.”

109. To plaintiffs’ knowledge, FDA has taken no other action in response to the

   Petition, despite the passage of nearly seven years since it was presented.

IV. FDA’s continuing delay and unlawful refusal to ban menthol.

110. Meanwhile, despite Director Zeller’s reported assurance in 2013 that “there was
   ‘no holdup’” concerning FDA’s determination or regulation of menthol in cigarettes, FDA for
   the next four years (i.e., Summer of 2013 – Summer of 2017) remained largely silent about its
   potential regulation of menthol cigarettes.

111. Around the same time, however, many other countries began moving to ban

   menthol in cigarettes.43

43 For example, in 2012, Brazil approved a ban on all flavors, including menthol, in all tobacco
   products. In 2016, the European Union banned all flavored cigarettes including menthol
   (effective 2020). And in 2017, Canada banned the sale of menthol cigarettes. See Campaign for
   Tobacco-Free Kids, Brazil’s Highest Court Upholds Ban on Flavored Tobacco Products (Feb. 1,
   2018). Available at https://www.tobaccofreekids.org/press-releases/2018_02_01_brazil-court-
112. Then in 2017, the agency finally seemed poised to take actual steps to regulate menthol cigarettes, as described below.

113. But by 2019, FDA and the other defendants had again backed away, continuing their ongoing pattern of delay and inaction on this critical public health issue.

A. 2017: FDA continues to delay addressing menthol in cigarettes.

114. In 2017, then-FDA Commissioner Scott Gottlieb announced a “new comprehensive plan for tobacco and nicotine regulation” that would serve as a multi-year roadmap to better protect children and significantly reduce tobacco-related disease and death. See FDA Announces Comprehensive Regulatory Plan to Shift Trajectory of Tobacco-Related Disease Death (July 27, 2017). Noting that over 480,000 deaths each year were caused by tobacco use, and that the direct healthcare and lost productivity costs totaled nearly $300 billion each year, the Commissioner noted that the agency would focus its efforts on starting a public dialogue about lowering nicotine levels in combustible cigarettes to non-addictive levels. See id.

115. Menthol, however, was relegated to further study and public comment. As part of that same announcement, FDA noted that it intended to issue yet another advance notice of proposed rulemaking to “seek public comment on the role that flavors (including menthol) in tobacco products play in attracting youth[.]” Id.

B. 2018: FDA Commissioner Gottlieb commits to banning menthol.

116. Then, on March 14, 2018, FDA Commissioner Gottlieb announced three advance notices of proposed rulemaking—one each (1) “to explore a product standard to lower nicotine in cigarettes to minimally or non-addictive levels”; (2) to “solicit additional comments upholds-flavor-ban (last visited June 13, 2020); World Health Organization, Advisory Note: Banning Menthol in Tobacco Products, 49–50 available at https://apps.who.int/iris/bitstream/handle/10665/205928/9789241510332_eng.pdf;jsessionid=6D55886EDA1A8FDA032CA2B42F4409FC?sequence=1. s. 44 Available at https://www.fda.gov/news-events/press-announcements/fda-announces-comprehensive-regulatory-plan-shift-trajectory-tobacco-related-disease-death.
and data related to the regulation of premium cigars”; and (3) “to seek comment on the role
that flavors—including menthol—play in initiation, use and cessation of tobacco products.”

FDA, Statement from FDA Commissioner Scott Gottlieb, M.D. (Mar. 14, 2018) (emphasis
added).45

117. As to menthol in cigarettes, FDA Commissioner Gottlieb noted that “youth
consistently report product flavoring as a leading reason for using tobacco products. Flavors
may disguise the taste of tobacco. But flavored cigarettes … are every bit as addictive as any
other tobacco products, have the same harmful health effects and may even make it harder to
quit. … Additionally, youth and young adult smokers are disproportionately more likely to
smoke menthol than nonmenthol cigarettes. And we know that youth who initiate smoking
with menthol cigarettes … may be at greater risk of progression from experimentation to
established smoking and nicotine dependence.” Statement from FDA Commissioner Scott
Gottlieb, M.D. (Mar. 19, 2018).46

45 Statement from FDA Commissioner Scott Gottlieb, M.D., on pivotal public health step to
dramatically reduce smoking rates by lowering nicotine in combustible cigarettes to minimally or
non-addictive levels (Mar. 14, 2018). Available at https://www.fda.gov/news-events/press-
announcements/statement-fda-commissioner-scott-gottlieb-md-pivotal-public-health-step-
dramatically-reduce-smoking.

The three advance notices of proposed rulemaking were later published that same month: See
FDA, Tobacco Product Standard for Nicotine Level of Combustible Cigarettes, Dkt. No. FDA-2017-N-6189,
https://www.federalregister.gov/documents/2018/03/16/2018-05345/tobacco-product-
standard-for-nicotine-level-of-combusted-cigarettes; FDA, Regulation of Flavors in Tobacco Products,
12901 (Mar. 26, 2018). Available at
https://www.federalregister.gov/documents/2018/03/16/2018-05345/tobacco-product-
standard-for-nicotine-level-of-combusted-cigaretttes.

46 Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to reduce tobacco use,
especially among youth, by exploring options to address the role of flavors—including menthol—in
tobacco products (Mar. 19, 2018). Available at https://www.fda.gov/news-events/press-
announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-reduce-tobacco-use-
especially-among-youth.
118. Following the submission of comments to these three advance notices, FDA Commissioner Gottlieb noted in an interview that “he was revisiting [FDA’s consideration of] the use of menthol in certain products, which has been of particular concern in African-American communities targeted by makers of menthol cigarettes like Newport and Kools in years past. ‘It was a mistake for the agency to back away of menthol,’ he said.” Sheila Kaplan, Altria to Stop Selling Some E-Cigarette Brands That Appeal to Youths, The New York Times (Oct. 25, 2018) (emphasis added).47

119. Accordingly, on November 18, 2018, then-FDA Commissioner Gottlieb announced that FDA would issue a Notice of Proposed Rulemaking “seek[ing] to ban menthol in combustible tobacco products, including cigarettes and cigars[.]” Statement from FDA Commissioner Scott Gottlieb, M.D. (Nov. 15, 2018).48

120. Commissioner Gottlieb described his reasoning as follows:

I’m deeply concerned about the availability of menthol-flavored cigarettes. I believe these menthol-flavored products represent one of the most common and pernicious routes by which kids initiate on combustible cigarettes. The menthol serves to mask some of the unattractive features of smoking that might otherwise discourage a child from smoking. Moreover, I believe that menthol products disproportionately and adversely affect

underserved communities. And as a matter of public health, they
exacerbate troubling disparities in health related to race and
socioeconomic status that are a major concern of mine.

…I noted that the popularity of menthol cigarettes with youth is
especially troubling. In fact, youth smokers are more likely to
use menthol cigarettes than any other age group. More than
half (54 percent) of youth smokers ages 12–17 use menthol
cigarettes, compared to less than one-third of smokers ages 35
and older. Prevalence of menthol use is even higher among
African-American youth, with data showing that seven out of 10
African-American youth smokers select menthol cigarettes.
And, … there’s no evidence to suggest that menthol-flavored
cigarettes may play a role in harm reduction for adult smokers.

Id.

121. Accordingly, FDA would “advance a Notice of Proposed Rulemaking that
would seek to ban menthol in combustible tobacco products, including cigarettes and cigars.”

Id. And significantly, FDA would “accelerate the proposed rulemaking process to ensure that
[its] policies on flavored tobacco products protect public health[.]” Id.

122. Such actions would be consistent with guidance from the National Centers for
Disease Control and Prevention (“CDC”), which noted the following “bottom line”:

a. “Tobacco companies add menthol to make cigarettes seem less harsh and more
appealing to new smokers and young people. …

b. Different groups of people—like some racial/ethnic minorities, LGBT people,
people with mental health conditions, etc.—are more likely to smoke menthol
cigarettes than the rest of the population. This is particularly true for African
Americans.
c. Some studies show that people who smoke menthol cigarettes have a harder
time quitting smoking than those who smoke non-menthol cigarettes.

d. We can help reduce menthol cigarette smoking and help people who smoke
menthol cigarettes to quit with policies that limit where menthol cigarettes are
sold and marketed, and by reaching out to groups that are more likely to smoke
menthol cigarettes.”49

C. 2019: Defendants abandon their plan to address menthol.

123. In March 2019, however, FDA Commissioner Scott Gottlieb resigned.

Norman E. “Ned” Sharpless, M.D. was then appointed Acting FDA Commissioner in April
2019.

124. And by June 2019, without any explanation, FDA reversed course and decided
not to initiate its previously announced rulemaking process.

1. FDA’s vision for the future omits addressing menthol.

125. On June 20, 2019, then-Acting FDA Commissioner Sharpless and defendant
Center for Tobacco Products Director Mitch Zeller announced FDA’s Achievements in Tobacco
Regulation Over the Past Decade and Beyond. See FDA, Achievements in Tobacco Regulation Over
the Past Decade and Beyond (June 20, 2019).50 Among other things, that announcement
noted the passage of the Tobacco Control Act, as well as FDA’s “groundbreaking plan for
tobacco and nicotine regulation,” including FDA’s plan “to take action on flavored cigars and
continue to explore other issues related to flavored tobacco products.” Id.

126. Absent from defendants’ announcement, however, was any mention of FDA
taking steps to address menthol in cigarettes.

49 Centers for Disease Control and Prevention, Menthol and Cigarettes (last reviewed May 18,
2020). Available at https://www.cdc.gov/tobacco/basic_information/tobacco_industry/menthol-
cigarettes/index.html.

50 Available at https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-
127. Similarly, on June 24, 2019, HHS published its inventory of rulemaking actions under development (“Spring 2019 Agenda”). See Regulatory Agenda, Ofc. of the Secretary, HHS, 84 Fed. Reg. 29623 (June 24, 2019). This Spring 2019 Agenda presented “the regulatory activities that the Department [i.e., HHS, FDA, and the defendant Center for Tobacco Products] expects to undertake in the foreseeable future,” id. at 29624 (citing various proposed rules, final rules, and long-term actions).

128. No plans to address menthol were included in this Regulatory Agenda by defendants. See HHS Regulatory Agenda, generally; HHS, Agency Rule List – Spring 2019.

129. Likewise, no plans to address menthol were included with HHS’s most recent Regulatory Agenda, published on December 26, 2019. See Regulatory Agenda, Ofc. of the Secretary, HHS, 84 Fed. Reg. 71129 (Dec. 26, 2019) (“Fall 2019 Agenda”).

2. The 2019 Unified Agenda omits any mention of menthol.

130. The same is true of the Unified Agenda, which is compiled by the Regulatory Information Services Center for the Office of Information and Regulatory Affairs (“OIRA”). See Regulatory Info. Services Ctr., Introduction to the Unified Agenda of Federal Regulatory and Deregulatory Actions, Dkt. No. 2019-12557, 84 Fed. Reg. 29591 (June 24, 2019); Regulatory

---


131. This Unified Agenda provides data on regulatory and deregulatory activities under development or review throughout the federal government—e.g., advance notices of proposed rulemaking, notices of proposed rulemaking, final rules, and long-term plans. See OIRA, About the Unified Agenda.55

132. And it confirms that defendants have no plans to undertake any regulatory action on menthol in cigarettes. See id. (identifying defendants’ regulatory actions at the pre-rule, proposed rule, and final rule stages of development and review). HHS does not even list menthol regulation on its list of “Long-Term Actions,” which identifies actions that the agency intends to pursue but does not anticipate taking action on in the following year. OIRA Long Term Actions, Agency Rule List – Spring 2019, HHS (identifying defendants’ long-term actions)56, OIRA Long Term Actions, Agency Rule List – Fall 2019, HHS57.

133. On this record, defendants’ unexplained and unjustifiable determination not to proceed with its own proposed rulemaking to ban menthol in combustible tobacco products violates the Tobacco Control Act and is unlawful.

---

55 Available at https://www.reginfo.gov/public/jsp/eAgenda/StaticContent/UA_About.myjsp.
56 Available at https://www.reginfo.gov/public/do/eAgendaMain?operation=OPERATION_GET_AGENCY_RULE_LIST&currentPubId=201904&showStage=longterm&agencyCd=0900&Image58.x=66&Image58.y=13; see generally Office of Information and Regulatory Affairs, About the Unified Agenda, available at https://www.reginfo.gov/public/jsp/eAgenda/UA_About.myjsp (“[A]n agency may list in the ‘Long-Term Actions’ section of its agenda those rules it expects will have the next regulatory action more than 12 months after publication of the agenda.”).
57 Available at https://www.reginfo.gov/public/do/eAgendaMain?operation=OPERATION_GET_AGENCY_RULE_LIST&currentPubId=201910&showStage=longterm&agencyCd=0900&csrf_token=243A419EF187585E8FFD83CD9CFA7CB8F1D8F1155635D087656DF62F1D717959D8C6B90FE425F27A717ECEC962B0EECE3D5800.
134. Over ten years ago, Congress directed defendants to address the public health harms caused by menthol in cigarettes. Since that time, however, defendants have simply pushed aside the mounting body of medical and scientific evidence that menthol in cigarettes harms the public health.

135. In 2011, FDA knew about these harms, as set forth by its own Scientific Advisory Committee. In 2013, FDA’s own findings and conclusions confirmed those harms to the public health. And in 2018, then-FDA Commissioner Gottlieb announced that FDA would advance a Notice of Proposed Rulemaking seeking to ban menthol in combustible tobacco products, including all cigarettes.\(^{58}\)

136. And yet, despite FDA’s knowledge of these public health harms, FDA and defendants have simply failed to do their job—i.e., protecting the public health. Accordingly, plaintiffs bring this action, seeking an Order from this Court granting the plaintiffs’ requested relief on the following claims:

**CLAIMS FOR RELIEF**

**Count I: Violation of the Administrative Procedure Act**

(5 U.S.C. §§ 555(b) & 706(1))

137. Plaintiffs incorporate by reference each of the foregoing allegations, above.

138. Section 555(b) of the Administrative Procedure Act requires each agency “to conclude a matter presented to it” “within a reasonable time,” 5 U.S.C. § 555(b). Section

\(^{58}\) Additional studies have since further concluded that removing menthol from cigarettes is likely to reduce youth smoking initiation, improve smoking cessation outcomes in adult smokers, and in turn, benefit public health. See, e.g., Villanti, Andrea C. et al., *Menthol Cigarettes and The Public Health Standard: A Systematic Review*, BMC Public Health (Dec. 29, 2017). Available at [https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4987-z](https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4987-z). And in a follow up study reviewing Canada’s menthol ban, at least one study found higher rates of quitting among daily and occasional menthol smokers, one year after the implementation of a menthol ban. See Chaiton M.O. et al., *Ban on menthol-flavoured tobacco products predicts cigarette cessation at 1 year: a population cohort study*, Tobacco Control (May 30, 2019). Available at [https://tobaccocontrol.bmj.com/content/early/2019/05/29/tobaccocontrol-2018-054841](https://tobaccocontrol.bmj.com/content/early/2019/05/29/tobaccocontrol-2018-054841).
706(1) provides that a reviewing court “shall compel agency action unlawfully withheld or unreasonably delayed,” 5 U.S.C. § 706(1).

139. Together, Sections 555(b) and 706(1) “indicate a congressional view that agencies should act within reasonable time frames and that courts designated by statute to review agency actions may play an important role in compelling agency action that has been improperly withheld or unreasonably delayed.” Telecommunications Research & Action Center v. FCC, 750 F.2d 70, 76–77 (D.C. Cir. 1984) (“TRAC”).

140. Accordingly, “delays that might be altogether reasonable in the sphere of economic regulation are less tolerable when human lives are at stake.” Cutler, 818 F.2d at 898 (footnotes omitted).59 “This is particularly true when the very purpose of the governing Act is to protect those lives.” Public Citizen Health Research Group v. Auchter, 702 F.2d 1150, 1157–58 (D.C. Cir. 1983).

141. To the extent defendants’ position is that they have not yet made a determination in accordance with 21 U.S.C. § 387g(a)(5) concerning whether to add menthol to the flavor ban list, id. § 387g(a)(1)(A), defendants’ failure to make such a determination constitutes agency action “unlawfully withheld or unreasonably delayed,” 5 U.S.C. § 706(1), and a failure by the agency to “conclude a matter presented” to the agency “within a reasonable time,” id. § 555(b).

142. At the time Congress enacted the Tobacco Control Act, Congress specifically recognized that menthol cigarettes “may pose unique health risks to those who smoke them.” H. Rept., Part 1 at 38. And as a result, Congress “urge[d] [FDA] to address these issues as quickly as practicable.” Id. Indeed, Congress believed that it would be “critical for [FDA] to move quickly to address the unique public health issues posed by menthol cigarettes.” Id. at 38–39.

59 See also Cutler, 818 F.2d at 898 n.162 (noting further that “the risk to human life need not be a certainty to justify expedition”).
To that end, Congress directed FDA to periodically reevaluate and “determine” whether the Act’s existing flavor standard “should be changed” to reflect new data and protect the public health. See 21 U.S.C. § 387g(a)(5).

Since that time, FDA has developed and interested parties have presented to FDA such new data and public health considerations, including the following:

a. The Tobacco Product Scientific Advisory Committee Report (2011);
b. The Industry Menthol Report (2011);
c. FDA’s own peer-reviewed evaluation of the science concerning menthol in cigarettes (2013);
d. FDA’s Advance Notice of Proposed Rulemaking, Menthol in Cigarettes, Tobacco Products, 78 Fed. Reg. 44484, and the comments received by FDA (2013); and

From these submissions, former FDA Commissioner Scott Gottlieb announced that FDA would begin the rulemaking process for banning menthol in combustible cigarettes.

And yet, without explanation, FDA and the defendants have declined to begin the rulemaking process.

Accordingly, FDA’s failure to make such a determination constitutes agency action “unlawfully withheld or unreasonably delayed,” 5 U.S.C. § 706(1), and a failure by the agency to “conclude a matter presented to it” “within a reasonable time,” id. § 555(b). See Sierra Club v. Gorsuch, 715 F.2d 653, 659 (D.C. Cir. 1983) (“judicial review of decisions not to regulate must not be frustrated by blind acceptance of an agency’s claim that a decision is still under study”) (emphasis in original); Cutler v. Hayes, 818 F.2d 879, 897 n.156 (D.C. Cir. 1987) (“[t]here comes a point when relegating issues to proceedings that go on without conclusion in any kind of reasonable time frame is tantamount to refusing to address the issues at all—and the result is a denial of justice”).
148. FDA’s unreasonable delay and inaction constitutes a violation of the Administrative Procedure Act.

Count II: Violation of the Administrative Procedure Act

(5 U.S.C. §§ 555(b) & 706(1)—Citizen Petition)

149. Plaintiffs incorporate by reference each of the foregoing allegations, above.

150. On or about April 12, 2013, plaintiff African American Tobacco Control Leadership Council (together with several other leading national organizations) submitted a Citizen Petition with FDA. See Tobacco Control Legal Consortium et al. Citizen Petition, Dkt. ID FDA-2013-P-0435-0001 (“Citizen Petition”).60 This Petition, among other things, asked FDA to do the following:

   a. Add menthol to the list of additives and constituents in the prohibition on characterizing flavors in cigarettes and cigarette smoke directed by section 907(a)(1)(A) of the Federal Food, Drug, and Cosmetic Act, see id. at 9–10 (i.e. prohibit menthol as a characterizing flavoring in cigarettes, see Citizen Pet., at 7); and

   b. Work with appropriate entities to provide support to smokers of menthol cigarettes who will quit as a result of the requested prohibition on menthol in cigarettes, see id. at 10.

151. Roughly six months later on October 7, 2013, defendant Mitchell Zeller (Director, Center for Tobacco Products), writing on behalf of the defendants, responded as follows: “FDA has been unable to reach a decision on your petition because it raises significant, complex issues requiring extensive review and analysis by Agency officials. As you may know, FDA issued an advance notice of proposed rulemaking on July 24, 2013, seeking comments, including comments on FDA’s preliminary scientific evaluation of public health issues related to the use of menthol in cigarettes, and data, research, or other information that may inform

regulatory actions FDA might take with respect to menthol in cigarettes (78 FR 44484). …

We will respond to your petition as soon as we have reached a decision on your request.”

152. FDA has a mandatory duty to respond to the citizen petition under the
Administrative Procedure Act and FDA’s own regulations adopted thereunder. See 5 U.S.C. §
553(e) (“Each agency shall give an interested person the right to petition for the issuance,
amendment, or repeal of a rule.”); 21 C.F.R. § 10.30 (e) (providing a 180-day timeframe within
which the agency must provide a response to the petitioner). See also Henley v. Food & Drug
Henley v. Food & Drug Admin., 77 F.3d 616 (2d Cir. 1996) (citing National Organization for Reform of
must consider the petition and must give written notice of the decision accompanied by an
explanatory statement.”).

153. To date, however, defendants have not yet substantively responded to plaintiff’s
Citizen Petition.

154. FDA’s unreasonable delay and inaction on addressing plaintiff’s Citizen Petition
violates the Administrative Procedure Act. See Pub. Citizen, 740 F.2d at 34–35 (remanding
citizen petition to district court for a determination whether agency had unduly delayed
responding to such petition).

**Count III: Violation of the Administrative Procedure Act**\(^{61}\)

(5 U.S.C. § 706(2)—Arbitrary and Capricious)

155. Plaintiffs incorporate by reference each of the foregoing allegations, above.

156. Plaintiffs allege this claim in the alternative to Counts I and II, see Fed. R. Civ.
P. 8(d), and in response to any argument by defendants that they have made a permissible
decision not to ban menthol.

---

\(^{61}\) This claim is pled subject to the Court’s November 12, 2020 Order (ECF No. 34), and to preserve any right of appeal.
157. Despite the overwhelming evidence that removing menthol cigarettes from the marketplace would benefit public health and defendant FDA’s own stated intention to ban menthol in combustible cigarettes for these reasons, defendants have declined to add menthol to the flavor ban list, id. § 387g(a)(1)(A).

158. Defendants’ calculated decision to allow menthol cigarettes to remain in the marketplace despite the overwhelming evidence that the Tobacco Act’s existing flavor standard “should be changed” to reflect new data and protect the public health, see 21 U.S.C. § 387g(a)(5), constitutes “agency action” subject to judicial review, a denial of plaintiff AATCLC’s Citizen Petition, and is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law, see 5 U.S.C. § 706(2).

159. Defendants have failed to provide any coherent explanation for this decision, failed to engage in any reasoned decision-making in reaching this determination, and reached a conclusion that contradicts the underlying record and the expert evidence.

160. Defendants’ unreasonable process and decision constitute violations of the Administrative Procedure Act.

REQUESTED RELIEF

WHEREFORE, Plaintiffs request that this Court enter the following:

1. An Order declaring defendants to be in violation of the Administrative Procedure Act;

2. An Order declaring defendants to be in violation of the Tobacco Control Act;

3. An Order directing defendants to begin the rulemaking process for adding menthol to the list of characterizing flavors banned by the Tobacco Control Act within 60 days of the date of any such Order;

4. An Order directing defendants to respond to the Citizen Petition submitted by plaintiff African American Tobacco Control Leadership Council et al.;
5. An Order directing defendants to provide for publication in the Federal Register, the basis for defendants’ decision to either (a) add menthol to the list of banned characterizing flavors for combustible cigarettes, or else (b) not add menthol to such list, within 60 days of the date of such Order;

6. An Order directing defendants to undertake and complete an evaluation of tobacco product standards to determine whether such standards should be changed to reflect new medical, scientific, or other technological data;

7. An Order awarding plaintiffs their reasonable costs and attorneys’ fees, under 28 U.S.C. § 2412; and


Respectfully submitted,

Date: December 3, 2020

/s/ Christopher K. Leung

Christopher K. Leung (SBN 210325)
Pollock Cohen LLP
60 Broad St., 24th Fl.
New York, NY 10004
Tel.: (212) 337-5361
Fax.: (347) 696-1227
Chris@PollockCohen.com

Counsel for Plaintiffs African American Tobacco Control Leadership Council, Action on Smoking and Health, American Medical Association, and National Medical Association